Frederick Locke, MD, summarizes outcomes from the ZUMA-1 clinical trial presented at ASH 2020

Smoking history in patients with myelodysplastic syndromes was tied to distinct genetic mutations, higher mutation burden, and worse survival in new data.

High-fiber diets may slow disease progression in precursor conditions of multiple myeloma and reduce complications after stem cell transplantation.

Daratumumab reduced the risk for progression or death compared with active monitoring among patients with high-risk smoldering multiple myeloma, new data show.

Some patients with mantle cell lymphoma do not benefit from consolidative autologous hematopoietic stem cell transplant, according to new data from ASH 2024.

From data that may soon lead to an approval in follicular lymphoma, to a pair of phase 2 trials, here are some key studies on indolent lymphomas from ASH 2024.

Adding tafasitamab to lenalidomide plus rituximab significantly improves PFS in patients with relapsed or refractory follicular lymphoma, new data show.

Use of epcoritamab resulted in an encouraging rate of complete remission and undetectable minimal residual disease in a small study of heavily pretreated R/R CLL.

A patient’s socioeconomic status can significantly affect their likelihood of receiving an allogeneic hematopoietic transplant for AML, according to new data.

CAR-T therapy may offer durable disease control and a potential path to cure for some patients with relapsed/refractory CLL, according to new long-term data.

Acalabrutinib plus venetoclax, with or without obinutuzumab, improves PFS in patients with untreated CLL compared with chemoimmunotherapy, new data show.

A survey of community-based cancer providers indicated that many have developed practices to address challenges in initiating venetoclax for patients with CLL.

Blinatumomab plus standard chemotherapy improves disease-free survival in pediatric patients with newly diagnosed B-cell acute lymphoblastic leukemia.